Agios Outlines $45m-$50m 2026 PK Deficiency Revenue as November 1 Sickle Cell PDUFA Approaches
Earnings Call Insights: Agios Pharmaceuticals (AGIO) Q2 2026 Management View - "We delivered a quarter marked by strong commercial performance, meaningful pipeline progress and continued portfolio discipline." (CEO Brian Goff) - "We delivered sustained commercial momentum with...